CCDC87

Across TCGA pan-cancer cohorts, CCDC87 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CCDC87 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher CCDC87 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC87 expression acts as an unfavorable survival marker.

THYM, ESCA, and LUAD are the cancer types where CCDC87 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	All	0.186	0.931	<.001	15	view →
ESCA	DFS	Median	II,III,IV	0.082	0.495	.002	12	view →
LUAD	OS	Median	III,IV	0.057	0.680	<.001	12	view →
HNSC	DFS	Median	All	0.206	0.711	.002	11	view →
LIHC	OS	Median	All	0.507	0.777	<.001	10	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.327	0.640	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CCDC87–THYM (OS)

Open the THYM breakdown →